SOUTH SAN FRANCISCO (dpa-AFX) - Lonza (LZAGF.PK), a supplier to the
pharmaceutical, healthcare and life-science industries, said that it agreed to
acquire the Genentech large-scale biologics manufacturing site in Vacaville,
California (US) from Roche for $1.2 billion.

The Vacaville (US) facility currently has a total bioreactor capacity of around
330,000 liters, making it one of the largest biologics manufacturing sites in
the world by volume.

As per the deal, about 750 Genentech employees at the Vacaville (US) facility
will be offered employment by Lonza.

Lonza plans to invest about 500 million Swiss francs in additional CAPEX to
upgrade the Vacaville (US) facility and enhance capabilities to satisfy demand
for the next generation of mammalian biologics therapies. The products currently
manufactured at the site by Roche will be supplied by Lonza, with committed
volumes over the medium term, phasing out over time as the site transitions to
serve alternative customers.

The transaction is expected to close in the second-half of 2024.

As the transaction is expected to be accretive to sales growth, Lonza has
updated its Mid-Term Guidance 2024 - 2028. Its sales growth range was set at 11
- 13% CAGR in CER, and has now been updated to 12 - 15%. Mid-Term Guidance for
CORE EBITDA margin and ROIC remains unchanged.



Copyright(c) 2024 RTTNews.com. All Rights Reserved

Copyright RTT News/dpa-AFX